Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
Interventions: BIOLOGICAL: Durvalumab|DRUG: Olaparib
Sponsor: OHSU Knight Cancer Institute
Collaborators: Oregon Health and Science University|Prospect Creek Foundation